pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
786
stories
2d
Court rejects Novo bid to block Lilly obesity drug ads
biopharma dive
2d
STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
stat
2d
Alphabet’s GV is one of biotech’s most influential corporate investors
biospace
2d
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
stat
3d
Recon: FDA approves treatments for prostate cancer, Crohn’s disease; US judge refuses to halt Lilly weight-loss drug ads
raps
3d
Corxel, an obesity drugmaker, to go public via SPAC deal
biopharma dive
3d
Corxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to Nasdaq
fiercebiotech
3d
Lilly’s music-loving, intense lead dealmaker knows what he wants
endpoints
5d
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
endpoints
6d
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
biospace
7d
Protein degrader specialist Lycia prices $318M IPO
biopharma dive
7d
GLP-1 compounder issues recall for copycat Zepbound
biopharma dive
7d
Roche affirms sales outlook amid doubts about its future
biopharma dive
7d
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
stat
8d
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
stat
8d
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
biopharma dive
8d
Drug prices climb past $250K as US patients balk at the pharmacy
biospace
8d
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
biospace
9d
Lilly’s retatrutide creeps closer to market for sleep apnea
endpoints
9d
The 6 biggest crossover rounds in biopharma history
biospace
9d
Biotech reverse mergers rebound to highest level since 2021 as PIPEs flood market: report
fiercebiotech
9d
STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole
stat
9d
STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
stat
9d
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
9d
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
9d
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
biospace
10d
EyePoint's Phase 3 failure; Lilly's China drug delivery deal
endpoints
10d
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
biospace
11d
Veradermics’ minoxidil pill improves hair coverage in men in Phase 3
biospace
11d
Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery
fiercebiotech
← prev
page 2 of 27
next →
